Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) - Bcl-2-like protein 1 is a protein encoded by the BCL2L1 gene. It belongs to BCL-2 family. It is a potent inhibitor of cell death. It inhibits activation of caspases. It regulate cell death by blocking the voltage-dependent anion channel by binding to it and preventing the release of the caspase activator (CYC1) from the mitochondrial membrane. It acts as a regulator of G2 checkpoint and progression to cytokinesis during mitosis.

Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) pipeline Target constitutes close to 11 molecules. Out of which approximately 8 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 3, 1 and 3 respectively. Similarly, the universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 1 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Infectious Disease and Musculoskeletal Disorders which include indications Solid Tumor, Non-Small Cell Lung Cancer, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Hepatocellular Carcinoma, Small-Cell Lung Cancer, Anaplastic Large Cell Lymphoma (ALCL), Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy, Bladder Cancer, Blood Cancer, Chronic Lymphocytic Leukemia (CLL), Chronic Myelomonocytic Leukemia (CMML), Diffuse Large B-Cell Lymphoma, Essential Thrombocythemia, Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma), Fibrosis, Follicular Lymphoma, Gastric Cancer, Head And Neck Cancer, Hematological Tumor, Hormone-Sensitive Prostate Cancer, Hypopharyngeal Cancer, Laryngeal Cancer, Lymphoblastic Lymphoma, Mantle Cell Lymphoma, Metastatic Melanoma, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections, Myelodysplastic Syndrome, Myelofibrosis, Natural Killer Cell Lymphomas, Neuroendocrine Tumors, Nodal Marginal Zone B-Cell Lymphoma, Peripheral T-Cell Lymphomas (PTCL), Polycythemia Vera, Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), Refractory Acute Myeloid Leukemia, Refractory Multiple Myeloma, Relapsed Acute Myeloid Leukemia, Relapsed Multiple Myeloma, Sezary Syndrome, Splenic Marginal Zone B-Cell Lymphoma, T-Cell Lymphomas and Unspecified B-Cell Lymphomas.

The latest report, outlays comprehensive information on the Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1)
  • The report reviews Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) targeted therapeutics
Reasons to Buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1)Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope


Introduction
Global Markets Direct Report Coverage
Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) – Overview
Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) – Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) – Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) – Companies Involved in Therapeutics Development
AbbVie Inc
Ascenta Therapeutics Inc
Ascentage Pharma Group International
AstraZeneca Plc
Dialectic Therapeutics Inc
Sirnaomics Ltd
Zentalis Pharmaceuticals Inc
Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) – Drug Profiles
753B – Drug Profile
ABT-737 – Drug Profile
AT-101 – Drug Profile
AZD-0466 – Drug Profile
BCL-xL Degrader – Drug Profile
DT-2216 – Drug Profile
navitoclax dihydrochloride – Drug Profile
pelcitoclax – Drug Profile
Small Molecules to Inhibit Mcl-1 and Bcl-xL for Oncology and MRSA Infections – Drug Profile
STP-369 – Drug Profile
Vaccine for Hormone-Sensitive Prostate Cancer – Drug Profile
Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) – Dormant Products
Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) – Discontinued Products
Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) – Product Development Milestones
Featured News & Press Releases
Jun 10, 2022: AbbVie presents investigational Navitoclax preliminary data in JAK inhibitor Naïve myelofibrosis patients
Apr 28, 2022: Ascentage Pharma to present data on APG-1252 at the 2022 American Society of Clinical Oncology Annual Meeting
Apr 13, 2022: AbbVie reports positive data from Phase II myelofibrosis therapy trial
Mar 14, 2022: Dialectic Therapeutics announces DT2216 has received orphan drug designation from the FDA for the treatment of T-Cell lymphoma
Dec 14, 2021: Ascentage Pharma presents on pelcitoclax at the 63rd American Society of Hematology (ASH) Annual Meeting
Nov 04, 2021: Ascentage Pharma to release latest data from pelcitoclax including a Chinese study demonstrating complete response
Sep 13, 2021: Ascentage Pharma announces latest data of its investigational Bcl-2/Bcl-xL inhibitor pelcitoclax (APG-1252) combined with osimertinib in patients with EGFR TKI-resistant non-small cell lung cancer
Sep 08, 2021: Ascentage Pharma announces latest data of its investigational Bcl-2/Bcl-xL inhibitor Pelcitoclax (APG-1252) combined with Osimertinib in patients with EGFR TKI-resistant non-small cell lung cancer
Aug 20, 2021: Dialectic Therapeutics receives $14.4 million Texas Company Product Development Research Award from the Cancer Prevention & Research Institute of Texas
May 19, 2021: Ascentage Pharma announces presentation on pelcitoclax at 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
Apr 21, 2021: Ascentage Pharma to present data on pelcitoclax (APG-1252) at 2021 ASCO Annual Meeting
Apr 12, 2021: Ascentage Pharma releases preclinical data on Pelcitoclax at AACR Annual Meeting 2021
Mar 03, 2021: Dialectic Therapeutics receives FDA clearance of IND application for lead antiapoptotic protein targeted degradation (APTaD) candidate DT2216
Feb 09, 2021: AZD0466 clinical DEP program global expansion
Oct 08, 2020: Ascentage Pharma's apoptosis-targeting drug candidate granted Orphan Drug Designation by the US FDA
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Table 1: Number of Products under Development by Stage of Development, 2022
Table 2: Number of Products under Development by Therapy Areas, 2022
Table 3: Number of Products under Development by Indications, 2022
Table 4: Number of Products under Development by Indications, 2022 (Contd..1)
Table 5: Number of Products under Development by Companies, 2022
Table 6: Products under Development by Companies, 2022
Table 7: Products under Development by Companies, 2022 (Contd..1)
Table 8: Products under Development by Companies, 2022 (Contd..2)
Table 9: Number of Products under Investigation by Universities/Institutes, 2022
Table 10: Products under Investigation by Universities/Institutes, 2022
Table 11: Number of Products by Stage and Mechanism of Actions, 2022
Table 12: Number of Products by Stage and Route of Administration, 2022
Table 13: Number of Products by Stage and Molecule Type, 2022
Table 14: Pipeline by AbbVie Inc, 2022
Table 15: Pipeline by Ascenta Therapeutics Inc, 2022
Table 16: Pipeline by Ascentage Pharma Group International, 2022
Table 17: Pipeline by AstraZeneca Plc, 2022
Table 18: Pipeline by Dialectic Therapeutics Inc, 2022
Table 19: Pipeline by Sirnaomics Ltd, 2022
Table 20: Pipeline by Zentalis Pharmaceuticals Inc, 2022
Table 21: Dormant Products, 2022
Table 22: Dormant Products, 2022 (Contd..1)
Table 23: Dormant Products, 2022 (Contd..2)
Table 24: Dormant Products, 2022 (Contd..3)
Table 25: Discontinued Products, 2022
List of Figures
Figure 1: Number of Products under Development by Stage of Development, 2022
Figure 2: Number of Products under Development by Therapy Areas, 2022
Figure 3: Number of Products under Development by Top 10 Indications, 2022
Figure 4: Number of Products by Stage and Mechanism of Actions, 2022
Figure 5: Number of Products by Routes of Administration, 2022
Figure 6: Number of Products by Stage and Routes of Administration, 2022
Figure 7: Number of Products by Molecule Types, 2022
Figure 8: Number of Products by Stage and Molecule Types, 2022

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings